Showing 2,041 - 2,060 results of 21,342 for search '(( significant decrease decrease ) OR ( significantly ((lower decrease) OR (we decrease)) ))', query time: 0.50s Refine Results
  1. 2041

    Random Forest structure with cross-validation. by Mingyue Sun (4638535)

    Published 2025
    “…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”
  2. 2042

    Land use change from 1990 to 2020. by Mingyue Sun (4638535)

    Published 2025
    “…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”
  3. 2043

    Geographic data. by Mingyue Sun (4638535)

    Published 2025
    “…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”
  4. 2044

    Classification accuracy. by Mingyue Sun (4638535)

    Published 2025
    “…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”
  5. 2045

    Data Sheet 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.pdf by Nourhen Agrebi (14151222)

    Published 2025
    “…</p>Objective<p>This study aims to elucidate the clinical implications of concurrent AICDA and IKBKB homozygous variants in a pediatric patient diagnosed with hyper-IgM syndrome.</p>Methods<p>We present immunological and genetic analysis of a Tunisian patient with two homozygous variants of uncertain significance (VUSs) in the IKBKB and AICDA genes, suspected of causing hyper-IgM and immune deficiency. …”
  6. 2046

    Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  7. 2047

    Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  8. 2048

    Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  9. 2049

    MRI grading systems’ diagnostic accuracy for MD. by Neda Azarpey (20308334)

    Published 2024
    “…<div><p>Background</p><p>The diagnosis of Meniere’s Disease (MD) presents significant challenges due to its complex symptomatology and the absence of definitive biomarkers. …”
  10. 2050

    MRI-based cochlear hydrops grading and PLE in MD. by Neda Azarpey (20308334)

    Published 2024
    “…<div><p>Background</p><p>The diagnosis of Meniere’s Disease (MD) presents significant challenges due to its complex symptomatology and the absence of definitive biomarkers. …”
  11. 2051

    Cochlear hydrops classification in MRI systems. by Neda Azarpey (20308334)

    Published 2024
    “…<div><p>Background</p><p>The diagnosis of Meniere’s Disease (MD) presents significant challenges due to its complex symptomatology and the absence of definitive biomarkers. …”
  12. 2052
  13. 2053

    S1 Data - by Jan Willem Koten (17743224)

    Published 2024
    Subjects:
  14. 2054
  15. 2055
  16. 2056
  17. 2057
  18. 2058
  19. 2059
  20. 2060